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INTRODUCTION 
Many people would rather take drugs orally than via 
injection, but the main problem with admin istering 
medications orally is that a pill often will not dissolve at 
exactly the right site in the gastrointestinal tract where the 
medicine can be absorbed in to the bloodstream. Hence a 
new drug delivery system i.e. magnetic p ill system was 
developed which can solve the problem by safely holding a 
pill in place in the intestine wherever it needs to be. The 
two main components of the system are conventional-
looking gelat in capsules that contain a tiny magnet and an 
external magnet. 
1,2,3
 In particular, the researchers envision 
that the technology could be used as a new drug delivery 
method for cancer drugs or drugs targeting GI diseases, as 
there are a number of therapeutics that would benefit from 
prolonged localization at their site of action or at the site of 
greatest absorption. The research is still in the early 
preclin ical stages, but it’s promising that the researchers 
have been able to overcome the hurdle of making the 
system safe for use in the body. According to the 
statement, even after holding a pill in place for 12 hours in 
the rats, the system applied a pressure on the intestinal wall 
that was less than 1/60th of what would be damaging. 
Magnetically localized pills serve as a platform technology 
for addressing a broad array of issues facing the 
implementation of disease therapies. In particular, 
therapeutics exhib iting optimal absorption within a limited 
region of the GI and those therapies that target GI ailments 
have immediate potential for exp loration by using our 
system and guidelines for magnetic pill retention. This 
technique is readily applicable to investigating the 
therapeutic benefit of prolonged local delivery of NAW 
therapeutics (e.g., acyclovir, bisphosphonates, furosemide, 
levodopa, and metformin) at their sites of greatest 
absorption (4, 5). Additionally, localized oral delivery of 
polymer nanoencapsulated proteins within specific regions 
of the GI, genes, and antibodies within the small intestines 
demonstrated tremendous potential to enable conversion to 
oral delivery o f bio logic therapies currently  delivered by 
injection (6–11). Similarly, localized oral delivery to the 
ileum would  expose vaccines to GALT increasing their 
contact with the immune system (4, 12) 
WORKING 
The two main components of the system are conventional-
looking gelat in capsules that contain a tiny magnet and an 
external magnet that can precisely sense the force between 
it and the pill and vary that force, by varying the external 
magnetic fo rce the capsule can be held at a specific 
location. The magnetic force is precisely controlled to 
avoid damaging surrounding tissue. The pill's retention 
works by creating an inter-magnetic force between the 
magnetic gelatin capsule and an external magnet. Magnetic 
capsule in the body placed t right place by the magnet 
outside which create a magnetic attraction and force to 
locate the magnetic capsule. 
2,13-15
 
Challenges for system 
The system is not the first attempt to guide pills 
magnetically, but it is the first one in which scientists can 
control the forces on a pill so that it’s safe to use in the 
body. They designed their system to sense the position of 
pills and hold them there with a min imum of force.  
The greatest challenges were quantifying the required  
force range for maintaining a magnetic pill in the small 
intestines and constructing a device that could maintain  
inter-magnetic forces within that range. 
 To check whether the pills is reach to the exact place 
can check by taking some blood samples and to 
check bioavailab ility of the same drug. 
2,14-16
 
Applications in Drug Delivery:  
 This technology is very applicable to humans 
especially in patients with cancer and diabetes and GI 
diseases. 
 The use of a magnet ensures the pill stays at the 
target therapeutic area for longer, which helps the 
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drug's uptake and bioavailability without damaging 
intestinal tissue. 
 Use for targeting GI cancers, other GI diseases, and 
being used to administer drugs orally that currently  
suffer from poor oral absorption 
16-18
 
 In particular, the researchers envision that the 
technology could be used as a new drug delivery 
method for cancer drugs or drugs targeting GI 
diseases, as there are a number o f therapeutics that 
would benefit from prolonged localization at their 
site of action or at the site of greatest absorption. 
 Another avenue for the application of magnetic p ill 
localization is the treatment of GI pathophysiologies 
including esophageal, gastric, intestinal, and 
colorectal cancers (19-22). 
 Magnetic localizat ion of chemotherapeutics at the 
site of GI tumors, which are simultaneously 
identifiable on X-ray fo llowing intravenous 
administration of radioopaque contrast, would enable 
localized dosing while min imizing side effects 
associated with systemic administration (11, 19).  
 Finally, magnetically localized oral delivery of 
therapeutics for GI diseases including severe cases of 
Crohn’s disease and acid reflux enables 
administration directly at the affected site without 
requiring direct visualization of the pathophysiology 
in question (4, 11) 
Futuristic approach 
The next  step is to move study to larger animal models and 
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